Literature DB >> 18756934

[Expression and significance of B7-H1 and its receptor PD-1 in human gastric carcinoma].

Shu-Man Liu1, Qing Meng, Qin-Xian Zhang, Sheng-Dian Wang, Zhan-Ju Liu, Xie-Fu Zhang.   

Abstract

OBJECTIVE: The B7-H1/PD-1 co-signaling pathway has recently been found to play a pivotal role in the immune evasion of tumor cells from host immune system. The aim of this study was to examine the B7-H1 and PD-1 expression and TILs status in gastric cancer and to elucidate the clinical relevance of B7-H1 and PD-1 to the pathogenesis of gastric carcinoma.
METHODS: Immunohistochemistry and ANAE histochemical staining were used to investigate the in situ expression of B7-H1 and PD-1 and TILs status in the gastric tissues. RT-PCR was used to explore B7-H1 and PD-1 expression at the transcriptional level. The B7-H1 expression at protein level was detected by Western blot.
RESULTS: Expression of B7-H1 and PD-1 was found to be increased in gastric carcinoma, but absent in normal gastric tissue. B7-H1 expression in gastric carcinoma was inversely correlated with TILs infiltration. B7-H1 but not PD-1 expression in tumor tissue was significantly correlated with some clinicopathhological variables including depth of invasion, lymph node metastasis and distant metastasis.
CONCLUSION: B7-H1 and PD-1 expressions are increased in gastric carcinoma. This signaling pathway may inhibit antitumor immune responses in gastric carcinoma. B7-H1 expression plays a critical role in the pathogenesis of human gastric carcinoma,and might be a promising prognostic marker and therapeutic target in the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18756934

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  8 in total

Review 1.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

2.  Program death 1 (PD1) haplotyping in patients with breast carcinoma.

Authors:  Mohammad Reza Haghshenas; Sirous Naeimi; Abdolrasoul Talei; Abbas Ghaderi; Nasrollah Erfani
Journal:  Mol Biol Rep       Date:  2010-11-27       Impact factor: 2.316

Review 3.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

4.  B7-H6 protein expression has no prognostic significance in human gastric carcinoma.

Authors:  Xiao-Juan Chen; Jin Shen; Guang-Bo Zhang; Wei-Chang Chen
Journal:  Pathol Oncol Res       Date:  2013-11-16       Impact factor: 3.201

Review 5.  Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies.

Authors:  Wenjing Dong; Mancheng Gong; Zhirong Shi; Jianjun Xiao; Junkai Zhang; Jiewen Peng
Journal:  PLoS One       Date:  2016-03-31       Impact factor: 3.240

Review 6.  The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma.

Authors:  Walid L Shaib; Jean Paul A Nammour; Harpaul Gill; Mayur Mody; Nabil F Saba
Journal:  J Clin Med       Date:  2016-11-14       Impact factor: 4.241

7.  Folic acid-functionalized polyethylenimine superparamagnetic iron oxide nanoparticles as theranostic agents for magnetic resonance imaging and PD-L1 siRNA delivery for gastric cancer.

Authors:  Xin Luo; Xia Peng; Jingying Hou; Shuyun Wu; Jun Shen; Lingyun Wang
Journal:  Int J Nanomedicine       Date:  2017-07-26

Review 8.  Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.

Authors:  Emily M Lin; Jun Gong; Samuel J Klempner; Joseph Chao
Journal:  World J Gastroenterol       Date:  2018-07-07       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.